Abbott schedules results. Abbott Laboratories stock trades 17.78 percent below its yearly high

Published on 10/20/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 21, 2026 before the market opens. Abbott Laboratories stock costs EUR 93.34 on October 20, 2026, above the EUR 92.46 Xetra close.

Results and valuation markers

Abbott scheduled its third-quarter report for October 21, 2026, before the market opens.
Second-quarter revenue reached USD 12.59 billion in 2026, up 13.00 percent year over year.
Abbott Laboratories stock trades at EUR 93.34 at 11:13 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.95 percent above the Xetra close of October 19, 2026.

Flatlay Glukosesensor Stethoskop Aktien Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Flatlay generischer Glukose-Sensor Stethoskop Reagenzgläser Aktien-Zertifikat ISIN-Karte Marmor Tisch, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at EUR 93.34 at Lang & Schwarz on October 20, 2026, at 11:13 a.m. CEST, up 0.95 percent versus the Xetra close of October 19, 2026, at EUR 92.46. Benzinga reported on October 19, 2026, that Abbott will publish third-quarter results before the market opens on October 21, 2026.

Results set the next test

The scheduled report follows a strong second quarter. MarketBeat said Abbott generated USD 12.59 billion of revenue in the second quarter of 2026, up 13.00 percent from the prior-year quarter. Adjusted earnings per share reached USD 1.31, beating the USD 1.28 consensus by USD 0.03.

The company also carried a full-year 2026 adjusted earnings-per-share outlook of USD 5.45 to USD 5.60, while the quarterly dividend was USD 0.63 per share, according to MarketBeat.

Three dates frame the stock

On July 16, 2026, Abbott reported USD 12.59 billion in second-quarter revenue and adjusted earnings per share of USD 1.31; on October 2, 2026, Rothschild and Co Redburn raised its target from USD 119.00 to USD 127.00; on October 21, 2026, Abbott is scheduled to report third-quarter results. The first two events are documented by MarketBeat, while the reporting date is covered by Benzinga.

What does the forecast imply for revenue?

Benzinga cited consensus expectations of USD 1.41 adjusted earnings per share and USD 12.99 billion of revenue for the third quarter of 2026, compared with USD 1.30 and USD 11.37 billion in the prior-year quarter. That revenue estimate implies 14.24 percent year-over-year growth, keeping the second-quarter expansion as the benchmark for the new report.

The next two dated items are the third-quarter results on October 21, 2026, and the quarterly dividend payment on November 16, 2026, with the latter date reported by MarketBeat.

Stock remains below its yearly high

Abbott Laboratories stock is 17.78 percent below its EUR 113.52 52-week high, while the EUR 70.10 low leaves a broad trading range as of October 20, 2026. The NYSE-listed company has a market capitalization of EUR 160.6 billion on the same date.

Abbott Laboratories stock was trading at EUR 93.34 at Lang & Schwarz on October 20, 2026, at 11:13 a.m. CEST, 0.95 percent above the Xetra close of October 19, 2026, at EUR 92.46. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.